원문정보
초록
영어
Overexpression of human epidermal growth factor receptor type 2 (HER2) protein is one of the prognostic factors for breast cancer, and HER2 is most likely to be recurrence when cancer metastasizes to lymph nodes. This study demonstrated the expression of the anti-HER2 camelid single domain antibody VHH in tobacco plant. And we confirmed the function of recombinant VHH for the treatment of breast cancer. The anti-HER2 VHH was fused to human IgG Fc domain along with KDEL endoplasmic reticulum (ER) (VHH-FcK) in a gene expression cassette. The plant gene expression cassette was transferred to tobacco plants using Agrobacterium-mediated transformation. The transformants were screened by PCR and western blots. ELISA confirmed the binding activity of purified anti-HER2 VHH-FcK to HER2 positive breast cancer cell line SK-BR-3. In conclusion, this study verified the possibility of anti-HER2 VHH-FcK as a therapeutic agent and suggests that the anti-breast cancer anti-HER2 VHH-FcK can be expressed, properly assembled and purified from plant expression system, which can be as an alternative system for antibody production. This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT)(2021R1F1A1063869).